Cardinal Capital Management Inc. Has $23.89 Million Stock Holdings in Becton, Dickinson and Company $BDX

Key Points

• Cardinal Capital Management cut its stake in Becton, Dickinson by 14.5% in Q4, selling 20,844 shares and now holds 123,084 shares valued at about $23.89 million.
• Becton, Dickinson reported Q results with EPS $2.91 (beat by $0.10) but revenue of $4.49 billion missed expectations, and the company set FY2026 guidance of $12.35–$12.65 EPS.
• Insiders sold 2,713 shares totaling roughly $536,881 in the last 90 days, while the company announced a $10 million share buyback authorization and pays a quarterly dividend of $1.05 (annual yield ~2.7%).

Cardinal Capital Management Inc. decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 14.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,084 shares of the medical instruments supplier's stock after selling 20,844 shares during the quarter. Cardinal Capital Management Inc.'s holdings in Becton, Dickinson and Company were worth $23,887,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in BDX. SOA Wealth Advisors LLC. lifted its holdings in shares of Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 95 shares in the last quarter. Activest Wealth Management lifted its holdings in shares of Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 97 shares in the last quarter. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth $25,000. Cornerstone Planning Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 463.3% during the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 139 shares in the last quarter. Finally, Accredited Wealth Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 70 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of the firm's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,610 shares of the firm's stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,713 shares of company stock worth $536,881 in the last 90 days. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Down 1.1%

Shares of NYSE BDX opened at $155.40 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The stock has a market capitalization of $44.25 billion, a P/E ratio of 25.35, a PEG ratio of 11.17 and a beta of 0.29. The stock's fifty day moving average is $171.94 and its 200 day moving average is $185.60.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $4.49 billion for the quarter, compared to analysts' expectations of $5.15 billion. During the same quarter last year, the business earned $3.43 earnings per share. Becton, Dickinson and Company's revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a share buyback plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th were given a $1.05 dividend. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 68.52%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BDX. Citigroup dropped their target price on Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating for the company in a report on Tuesday, February 10th. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a "buy" rating in a report on Wednesday, January 7th. Barclays began coverage on Becton, Dickinson and Company in a report on Tuesday, February 10th. They set an "overweight" rating and a $202.00 target price for the company. JPMorgan Chase & Co. dropped their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating for the company in a report on Tuesday, February 10th. Finally, Bank of America lifted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a "neutral" rating in a report on Monday, January 5th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $191.62.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.